Kyntra Bio Inc (KYNB) Stock Analysis
Verdict: WATCH (do not buy)
Artificially inflated net income masks a deteriorating revenue base and severe clinical-stage cash burn, despite a zero-debt balance sheet.
Investment score: 44/100
Analysis as of
Is Kyntra Bio Inc stock worth reviewing? The TradeMates thesis
KYNB is a micro-cap biotech whose metrics are heavily distorted by non-recurring events. Despite a $28 price target, the -690% operating margin and massive projected losses suggest the company is burning through its $47.8M cash reserve with no clear path to sustainable revenue.
7-factor investment score
- Valuation: 55/100 (weight 20%)
- Financial Health: 30/100 (weight 15%)
- Technical Momentum: 25/100 (weight 15%)
- Earnings Quality: 50/100 (weight 15%)
- Insider Sentiment: 60/100 (weight 10%)
- Analyst Consensus: 40/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
Kyntra Bio Inc opportunities and risks
What speaks for KYNB
- Cash-Rich Balance Sheet
What speaks against KYNB
- Terminal Cash Burn
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| KYNB | 0.2x | 3.7x | 0.2x | 26.7% | 1498.0% | -77.2% |
| SKYE | n/a | 0.0x | n/a | 0.0% | 0.0% | -146.9% |
| SER | n/a | 160.0x | 0.0x | 73.8% | -16359.2% | -87.7% |
| GRDX | n/a | 427.5x | n/a | -3398.9% | -18078.3% | -36.8% |
| CRVO | n/a | 87.5x | n/a | 100.0% | -9311.6% | -97.6% |
| DYAI | n/a | 9.2x | n/a | 31.3% | -245.1% | -20.8% |
| Peer median | n/a | 87.5x | n/a | 31.3% | -9311.6% | -87.7% |
Frequently asked questions about Kyntra Bio Inc (KYNB)
Is KYNB stock a good investment?
The TradeMates model rates Kyntra Bio Inc as WATCH (do not buy) with an investment score of 44/100. KYNB is a micro-cap biotech whose metrics are heavily distorted by non-recurring events. Despite a $28 price target, the -690% operating margin and massive projected losses suggest the company is burning through its $47.8M cash reserve with no clear path to sustainable revenue. This is algorithmic model output, not personal investment advice.
Is KYNB stock a buy?
The TradeMates model verdict for KYNB is WATCH (do not buy) with an investment score of 44/100. Treat this as a model signal to review, not a personal buy recommendation.